Review



custom bioactive compound library  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    TargetMol custom bioactive compound library
    Custom Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 109 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Bioactive+Compound+Library/pm42933337-145-13-17
    Average 97 stars, based on 109 article reviews
    custom bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    other:

    Article Title: Cell Painting in activated cells illuminates phenotypic dark space and drug mechanisms of action
    Article Snippet: We obtained a library of 8,387 bioactive compounds (L4000-CUST, listed in Supplementary Data 1) from TargetMol.

    Article Title: P2Y12-oriented computational screening and functional validation identify antiplatelet compounds with antithrombotic activity.
    Article Snippet: AutoDock Vina10 was used to dock the compound into the protein pocket and choose the best docking pose for the next analysis.

    Article Title: MD2-IN-1 restores microglial lysosomal function and attenuates amyloid pathology through TREM2-associated signaling in 5×FAD mice.
    Article Snippet: Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial adaptation during Alzheimer’s disease (AD), yet the development of small-molecule modulators associated with TREM2 signaling remains limited.. Here, through a consensus pharmacophore-guided virtual screening strategy, MD2-IN-1 was identified as a candidate small molecule associated with TREM2 signaling.. Biolayer interferometry and cellular thermal shift assays supported cellular target engagement related to TREM2 (KD= 13.85 μM).

    Positive Control:

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Molecular Weight:

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Solvent:

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Drug discovery:

    Article Title: Targeting the CD4 + effector memory T cells re-expressing CD45RA suppressor galectin-7: a multi-omics-guided therapeutic strategy for idiopathic pulmonary fibrosis.
    Article Snippet: .. A library of approximately 20,000 bioactive compounds (TargetMol Bioactive Compound Library) was prepared using the LigPrep module (Schrödinger, LLC, New York, NY, 2021). ..

    Article Title: A secreted Cryptosporidium parvum dipeptidyl peptidase (CpDPP1) is targetable for developing cryptosporidial therapeutics.
    Article Snippet: .. Potential rCpDPP1 inhibitors were identified using the fluorescencebased activity assay to screen a custom Bioactive Compound Library (Topscience, Shanghai, China) comprising 5000 small molecules with annotated bioactivities. ..

    Article Title: Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening
    Article Snippet: .. Preprocessing of the small-molecule library and virtual screening The commercially available TargetMol Bioactive Compound Library (L4000), containing 17,284 small molecules, was used in this study. ..

    Activity Assay:

    Article Title: A secreted Cryptosporidium parvum dipeptidyl peptidase (CpDPP1) is targetable for developing cryptosporidial therapeutics.
    Article Snippet: .. Potential rCpDPP1 inhibitors were identified using the fluorescencebased activity assay to screen a custom Bioactive Compound Library (Topscience, Shanghai, China) comprising 5000 small molecules with annotated bioactivities. ..

    Screening:

    Article Title: Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening
    Article Snippet: .. Preprocessing of the small-molecule library and virtual screening The commercially available TargetMol Bioactive Compound Library (L4000), containing 17,284 small molecules, was used in this study. ..



    Similar Products

    95
    TargetMol clinical stage compounds
    Clinical Stage Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/10__1021_slash_acs__jmedchem__6c01726-423-7-11
    Average 95 stars, based on 1 article reviews
    clinical stage compounds - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals natural terpenoid compound library
    Primary screening of a <t>terpenoid</t> <t>compound</t> <t>library</t> against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
    Natural Terpenoid Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Compound/pmc13748739-35-1-11
    Average 96 stars, based on 1 article reviews
    natural terpenoid compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    TargetMol anti cardiovascular disease compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Anti Cardiovascular Disease Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Anti-Cardiovascular+Disease+Compound+Library/pmc13748904-58-22-21
    Average 90 stars, based on 1 article reviews
    anti cardiovascular disease compound library - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    TargetMol pharmacopeia compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Pharmacopeia Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/FDA-Approved+Drug+Library/10__1038_slash_s41419___026___09401___w-74-10-7
    Average 96 stars, based on 1 article reviews
    pharmacopeia compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    TargetMol compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/pm42966158-42-0-11
    Average 95 stars, based on 1 article reviews
    compound library - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    97
    TargetMol custom bioactive compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Custom Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Bioactive+Compound+Library/pm42933337-145-13-17
    Average 97 stars, based on 1 article reviews
    custom bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    Selleck Chemicals organoid based drug screening
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Organoid Based Drug Screening, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Epigenetics+Compound+Library/pmc13683295-285-4-13
    Average 94 stars, based on 1 article reviews
    organoid based drug screening - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol drug screen
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Drug Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Cell+Cycle+Compound+Library/pm42901431-305-15-20
    Average 94 stars, based on 1 article reviews
    drug screen - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol endoplasmic reticulum er stress
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Endoplasmic Reticulum Er Stress, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Endoplasmic+Reticulum+Stress+Compound+Library/pm42896314-137-3-21
    Average 94 stars, based on 1 article reviews
    endoplasmic reticulum er stress - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    TargetMol ferroptosis
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Ferroptosis, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Ferroptosis+Compound+Library/pm42896314-137-8-21
    Average 96 stars, based on 1 article reviews
    ferroptosis - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Journal: JAC-Antimicrobial Resistance

    Article Title: Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library

    doi: 10.1093/jacamr/dlag250

    Figure Lengend Snippet: Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Article Snippet: A natural terpenoid compound library containing 354 compounds was purchased from Selleck Chemicals (L1420, Selleck Chemicals, USA).

    Techniques: Screening, Drug discovery, Cell Culture, Concentration Assay, Inhibition, Bacteria, Negative Control, Positive Control

    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Targeting a Calcium‐Associated Mitochondrial Vulnerability in TET2‐Deficient Myeloid Cells

    doi: 10.1002/advs.78748

    Figure Lengend Snippet: Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: To identify compounds that preferentially compromise TET2 ‐KD macrophages, we performed chemical‐genetic screening using 489 cardiovascular disease‐related bioactive compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library (Figure and Extended Data Table ).

    Techniques: Screening, Derivative Assay, Drug discovery, Preserving, Biomarker Discovery, Alamar Blue Assay, Activity Assay, MTS Assay, Transfection, Enzyme-linked Immunosorbent Assay, RNA Sequencing